{"created":"2021-03-01T06:28:46.593627+00:00","id":23510,"links":{},"metadata":{"_buckets":{"deposit":"4a4156f7-a5cd-4103-b56d-041475c7530a"},"_deposit":{"id":"23510","owners":[],"pid":{"revision_id":0,"type":"depid","value":"23510"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00023510","sets":["453:456","471:537:538:1223"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Clinical and Virological Study on The Antiviral Treatment of Chronic Type B Hepatitis Positive for HBe Antigen"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1988-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"210","bibliographicPageStart":"201","bibliographicVolumeNumber":"102","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Forty three patients with HBeAg-positive chronic hepatitis B were treated with Ara-A or IFN alone and in combination to evaluate their efficacy and  indication. Combination therapy was more effective than treatment of Ara-A or IFN alone in lowering DNAP activity and cut off index of HBeAg during the treatment and 12 months after cessation of the therapy. HBeAg turned negative in six of 9 patients (66.7%) treated with combination therapy, while 2 of 11 patients (19.2%) with Ara-A alone and 6 of 23 patients (26.1%) with IFN alone turned negative within 12 months after stopping of therapy. The fall of DNAP activity and cut off index of HBeAg in combination therapy were more remarkable than treatment of IFN alone, even though the levels of 2', 5' oligoadenylate synthetase activity in peripheral blood mononuclear cells were same in patients undergoing these two regimens. This might suggest that the suppression of DNAP activity by Ara-A induce favorable antiviral effect by the following combination therapy with IFN. To obtain higher clearance rate of HBeAg, antiviral therapy should be indicated in patients younger than 35 y. 0. with histologically chronic active hepatitis and GPT levels higher than 150 IU/L. The indication of antiviral agent alone or combination should be selected by the levels of HBV replication represented by DNAP and HBeAg at pretreatment.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"141465","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Kawaguchi, Hideki"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"川口, 秀輝"}],"nameIdentifiers":[{"nameIdentifier":"141464","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-19"}],"displaytype":"detail","filename":"102(4)_201-210.pdf","filesize":[{"value":"2.7 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"102(4)_201-210.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/23510/files/102(4)_201-210.pdf"},"version_id":"b83a2855-5998-46ed-ab4f-1e07270d9d2f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Adenine arabinoside (Ara-A)","subitem_subject_scheme":"Other"},{"subitem_subject":"Interferon (IFN)","subitem_subject_scheme":"Other"},{"subitem_subject":"Combination therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"HBeAg/anti-HBe system","subitem_subject_scheme":"Other"},{"subitem_subject":"2', 5' oligoadenylate synthetase (2, 5 As)","subitem_subject_scheme":"Other"},{"subitem_subject":"アデニシアラビノシド","subitem_subject_scheme":"Other"},{"subitem_subject":"インターフェロン","subitem_subject_scheme":"Other"},{"subitem_subject":"併用療法","subitem_subject_scheme":"Other"},{"subitem_subject":"HBe 抗原抗体系","subitem_subject_scheme":"Other"},{"subitem_subject":"2', 5' オリゴアデニル酸合成酵素","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"HBe 抗原陽性慢性肝炎の抗ウイルス療法に関する研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HBe 抗原陽性慢性肝炎の抗ウイルス療法に関する研究"},{"subitem_title":"HBe 抗原陽性慢性肝炎の抗ウイルス療法に関する研究","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1223"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-04-06"},"publish_date":"2016-04-06","publish_status":"0","recid":"23510","relation_version_is_last":true,"title":["HBe 抗原陽性慢性肝炎の抗ウイルス療法に関する研究"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:53:42.758315+00:00"}